Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Myeloid Leukemia, Chronic, Chronic Phase Clinical Trial

— OPTIC  

Official title:

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02467270
• Other study ID #: AP24534-14-203
• Secondary ID: 2014-001617-1215
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 30, 2015
• Est. completion date: June 1, 2024

Study information

• Verified date: February 2024
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by <=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.

Description:

The drug being tested in this study is ponatinib. This study will characterize the safety and efficacy of ponatinib over a range of 3 starting doses.

The study will enroll 276 participants in 3 cohorts and each cohort will have 92 participants. All the participants will be randomized to receive once-daily oral administration of 1 of 3 starting doses of ponatinib:

• Cohort A: 45 mg ponatinib tablet

• Cohort B: 30 mg ponatinib tablet

• Cohort C: 15 mg ponatinib tablet

The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional treatment continuation period. Participants will be treated with their randomized dose of study drug in the Main Treatment Period until the occurrence of at least one of the following: absence of CHR by 3 months, absence of MCyR at 12 months, absence of <=1% BCR-ABL1IS at 12 months, loss of <=1% BCR-ABL1IS development of intolerance, or completion of all 24 cycles of treatment (whichever occurs first). Following completion of approximately 5 years or following early withdrawal, participants may enter into an optional treatment continuation period.

This multi-center trial will be conducted in the United States, United Kingdom, Republic of Korea, Spain, France, Taiwan, Australia, Canada, Italy, Chile, Japan, Germany, Argentina, Poland, Czech Republic, Denmark, Hong Kong, Portugal, Russia, Singapore, Switzerland, and Sweden. The overall time to participate in this study is approximately 96 months. Participants will make a final visit to the clinic approximately 30 days after the last dose of study treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 283
• Est. completion date: June 1, 2024
• Est. primary completion date: April 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Have chronic phase-chronic myelogenous leukemia/chronic myeloid leukemia (CP-CML) and have received at least two prior tyrosine kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T315I mutation after receiving any number of prior TKI.

o] The diagnosis of chronic myeloid leukemia (CML) will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following: i <15% blasts in bone marrow ii <30% blasts plus promyelocytes in bone marrow iii <20% basophils in peripheral blood. iv >= 100*10^9/liter (L) platelets (>=100,000/mm^3). v No evidence of extramedullary disease except hepatosplenomegaly vi No prior diagnosis of AP-CML, and BP-CML o] Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome.

i Variant translocations are only allowed provided they meet inclusion criterion 1d.

o] Resistance to prior TKI therapy is defined as follows (participants must meet at least 1 criterion): i Three months after the initiation of prior TKI therapy: No cytogenetic response (>95% Ph+) or failure to achieve CHR or new mutation ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or Ph+ >65% or new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS >10% and/or Ph+ >35% or new mutation iv At any time after the initiation of prior TKI therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time after the initiation of prior TKI therapy, the development of new clonal evolution vi At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS transcript level of >=1% or new mutation o] >1% of BCR-ABL1IS as shown by real-time polymerase chain reaction

2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

3. Have adequate renal function as defined by the following criterion:

o] Serum creatinine <=1.5*ULN for institution o] Estimated creatinine clearance >=30 milliliter per minute (mL/min) (Cockcroft-Gault formula)

4. Have adequate hepatic function as defined by the following criteria:

o] Total serum bilirubin <=1.5*ULN, unless due to Gilbert's syndrome o] Alanine transaminase (ALT) <=2.5*ULN, or <=5*ULN if leukemic infiltration of the liver is present o] Aspartate transaminase (AST) <=2.5*ULN, or <=5*ULN if leukemic infiltration of the liver is present

5. Have normal pancreatic status as defined by the following criterion:

o] Serum lipase and amylase <=1.5*ULN

6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening electrocardiogram (ECG) evaluation, defined as QTcF of <=450 milliseconds (ms) in males or <=470 ms in females.

7. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).

8. Agree to use a highly effective form of contraception with sexual partners from randomization through at least 4 months after the end of treatment (for female and male participants who are fertile).

9. Provide written informed consent.

10. Be willing and able to comply with scheduled visits and study procedures.

11. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade <=1.

Exclusion Criteria:

1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug.

2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib, or have not recovered (>grade 1 by NCI CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered.

3. Have undergone autologous or allogeneic stem cell transplant <60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy.

4. Are being considered for hematopoietic stem cell transplant (HSCT) within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial).

5. Are taking medications with a known risk of Torsades de Pointes.

6. Have previously been treated with ponatinib.

7. Have active CNS disease as evidenced by cytology or pathology; in the absence of clinical CNS disease, lumbar puncture is not required. History itself of CNS involvement is not exclusionary if CNS has been cleared with a documented negative lumbar puncture.

8. Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

o] Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or Transient Ischemic Attack (TIA) o] Any history of peripheral vascular infarction, including visceral infarction o] Any revascularization procedure, including the placement of a stent o] Congestive heart failure (CHF) (New York Heart Association [NYHA] class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment o] History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia o] Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment

9. Have uncontrolled hypertension (that is, >150 and >90 for systolic blood pressure (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor.

10. Have poorly controlled diabetes defined as HbA1c values of >7.5%. Participants with preexisting, well-controlled diabetes are not excluded.

11. Have a significant bleeding disorder unrelated to CML.

12. Have a history of alcohol abuse.

13. Have a history of either acute pancreatitis within 1 year of study enrollment or of chronic pancreatitis.

14. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug.

15. Have a history of another malignancy, other than cervical cancer in situ or basal cell or squamous cell carcinoma of the skin; the exception is if participants have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy.

16. Are pregnant or lactating.

17. Have undergone major surgery (with the exception of minor surgical procedures, such as catheter placement or BM biopsy) within 14 days prior to first dose of ponatinib.

18. Have an active infection which requires intravenous antibiotics.

19. Have a known history of human immunodeficiency virus infection; testing is not required in the absence of prior documentation or known history.

20. Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with the evaluation of the drug.

21. Have hypersensitivity to the ponatinib active substance or to any of its inactive ingredients.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase
• Myeloid Leukemia, Chronic, Chronic Phase

Intervention

Drug:
• Ponatinib
Tablet, taken orally once daily.

Locations

Country	Name	City	State
Argentina	Fundaleu	Ciudad Autonoma de Buenos Aires	Buenos Aires
Argentina	Hospital General de Agudo Jose Maria Ramos Mejia	Ciudad Autonoma de Buenos Aires	Buenos Aires
Argentina	Hospital Italiano La Plata	La Plata	Buenos Aires
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Royal North Shore Hospital	Saint Leonards	New South Wales
Canada	Jewish General Hospital	Montreal	Quebec
Canada	Saskatchewan Cancer Agency	Regina	Saskatchewan
Canada	Princess Margaret Hospital - Toronto	Toronto	Ontario
Chile	Hospital del Salvador	Providencia	Santiago
Chile	Centro de Investigaciones Clinicas Vina del Mar	Vina del Mar	Valparaiso
Czechia	Fakultni Nemocnice Olomouc	Olomouc
Czechia	Ustav Hematologie a Krevni Transfuze Praha	Prague	Praha
Denmark	Aarhus University Hospital	Aarhus C	\Aarhus
France	Center Hospitalier Universitaire d'Angers	Angers Cedex 9	PAYS DE LA Loire
France	Centre de Lutte Contre le Cancer - Institut Bergonie	Bordeaux	Aquitaine
France	Centre Hospitalier Regional Universitaire de Lille	Lille cedex	NORD Pas-de-calais
France	Centre Hospitalier Universitaire de Nantes Hotel Dieu	Nantes Cedex 1	PAYS DE LA Loire
France	Centre Hospitalier Universitaire de Nice Hopital l'Archet	Nice Cedex 3	Provence Alpes COTE D'azur
France	Centre Hospitalier Universitaire de Poitiers	Poitiers Cedex	Poitou-charentes
France	Institut Universitaire du Cancer de Toulouse Oncopole	Toulouse Cedex 9	Midi-pyrenees
France	Centre Hospitalier Universitaire de Nancy Hopital de Brabois	Vandoeuvre les Nancy	Lorraine
Germany	Uniklinik RWTH Aachen	Aachen	Nordrhein-westfalen
Germany	Charite Universitatsmedizin Berlin	Berlin
Germany	Universitaetsklinikum Essen	Essen	Nordrhein-westfalen
Germany	Universitatsklinikum Hamburg-Eppendorf	Hamburg
Germany	Universitatsklinikum Jena	Jena	Thuringen
Germany	Universitaetsklinikum Heidelberg	Mannheim	Baden-wuerttemberg
Germany	Universitatsmedizin Rostock	Rostock	Mecklenburg-vorpommern
Germany	Universitatsklinikum Ulm	Ulm	Baden-wuerttemberg
Hong Kong	Queen Mary Hospital	Hong Kong
Italy	Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele	Catania
Italy	Azienda Ospedaliera Universitaria San Martino	Genova
Italy	Azienda Ospedaliera San Gerardo di Monza	Monza	Monza E Brianza
Italy	Azienda Ospedaliera Ospedali Riuniti Marche Nord	Pesaro	Pesaro E Urbino
Italy	Azienda Sanitaria Locale di Pescara Ospedale Civile Dello Spirito Santo	Pescara
Italy	Sapienza Universita Di Roma	Roma
Italy	AOUI - Ospedale Policlinico "Giambattista Rossi" di Borgo Roma	Verona
Korea, Republic of	The Catholic University of Korea, Seoul St. Mary's Hospital	Seoul
Poland	Uniwersyteckie Centrum Kliniczne	Gdansk	Pomorskie
Poland	Malopolskie Centrum Medyczne	Krakow	Malopolskie
Poland	Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi	Lodz	Lodzkie
Poland	Instytut Hematologii i Transfuzjologii	Warszawa	Mazowieckie
Poland	Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu	Wroclaw	Dolnoslaskie
Portugal	Instituto Portugues de Oncologia de Lisboa Francisco Gentil	Lisboa
Portugal	Centro Hospitalar Sao Joao	Porto
Russian Federation	Chelyabinsk Regional Clinical Hospital	Chelyabinsk
Russian Federation	Kemerovo Regional Clinical Hospital	Kemerovo
Russian Federation	GBUZ Moscow Clinical Scientific Center DZM	Moscow
Russian Federation	Russian Academy of Medical Science	Moscow
Russian Federation	Rostov State Medical University	Rostov-na-Donu	Rostov
Russian Federation	Almazov Federal North-West Medical Research Centre of Department of Health of Russian Federation	Saint Petersburg
Russian Federation	FGU Russian Scientific Research Institute of Hematology and Transfusiology	Saint Petersburg
Russian Federation	Samara State Medical University	Samara
Russian Federation	Saratov State Medical University	Saratov
Singapore	Singapore General Hospital	Singapore
Spain	Hospital Clinic i Provincial de Barcelona	Barcelona
Spain	Hospital Universitario de Gran Canaria Doctor Nergrin	Las Palmas de Gran Canaria	LAS Palmas
Spain	Hospital Universitario de La Princesa	Madrid
Spain	Hospital Universitario Ramon Y Cajal	Madrid
Spain	Hospital Regional Universitario Carlos Haya	Malaga	Andalucia
Spain	Hospital Clinico Universitario de Valencia	Valencia
Sweden	Akademiska Sjukhuset	Uppsala
Switzerland	University Hospital Zurich	Zurich
Taiwan	National Taiwan University Hospital	Taipei
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow	Scotland
United Kingdom	Royal Liverpool University Hospital NHS Trust	Liverpool	England
United Kingdom	Imperial College Healthcare NHS Trust	London	England
United Kingdom	King's College Hospital NHS Foundation Trust	London	England
United Kingdom	Nottingham City Hospital NHS Trust	Nottingham	England
United Kingdom	Churchill Hospital	Oxford	England
United States	Michigan Medicine	Ann Arbor	Michigan
United States	Emory University Winship Cancer Institute	Atlanta	Georgia
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	Cleveland Clinic Taussig Cancer Institute Main Campus	Cleveland	Ohio
United States	Barbara Ann Karmanos Cancer Institute	Detroit	Michigan
United States	Duke University Medical Center	Durham	North Carolina
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	MD Anderson Cancer Center	Houston	Texas
United States	Indiana Blood & Marrow Transplantation	Indianapolis	Indiana
United States	University of Minnesota Medical School	Minneapolis	Minnesota
United States	Memorial Sloan-Kettering Cancer Center - New York	New York	New York
United States	NewYork-Presbyterian Weill Cornell Medical Center	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Abramson Cancer Center	Philadelphia	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	University of Utah Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  Chile,  Czechia,  Denmark,  France,  Germany,  Hong Kong,  Italy,  Korea, Republic of,  Poland,  Portugal,  Russian Federation,  Singapore,  Spain,  Sweden,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12	MR2 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL <=1% Breakpoint Cluster Region-Abelson Transcript Level as Measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.	12 months after the first dose of study treatment
Secondary	Percentage of Participants With Major Molecular Response (MMR/MR3)	MMR/MR3 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL =0.1% on the international scale (equivalent to a 3-log reduction in transcript).	12 months after the first dose of study treatment
Secondary	Percentage of Participants With Major Cytogenetic Response (MCyR)	MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: >0 to 35% Ph + metaphases.	12 months after the first dose of study treatment
Secondary	Duration of Major Molecular Response (MMR/MR3)	Duration of MMR/MR3 is defined as the interval between the first assessment at which the criteria for <=0.1% MMR are met until the earliest date at which loss of <=0.1% MMR occurs, or the criteria for progression are met. Progression to accelerated phase (AP) is defined as: >= 15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast Phase (BP) is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.	Baseline up to approximately 8 years
Secondary	Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)	Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.	From first dose up to 30 days after last dose of the study drug up to data cut-off date: 31 May 2020 (Up to approximately 5 years)
Secondary	Percentage of Participants With Complete Cytogenetic Response (CCyR)	Cytogenetic response is defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR is defined as 0% Ph+ metaphases.	Month 12
Secondary	Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response (MR4.5)	MR4 is defined as <=0.01% BCR-ABL1IS. MR 4.5 is defined as <=0.0032% BCR-ALB1IS.	Up to approximately 8 years
Secondary	Percentage of Participants With Molecular Response 1 (MR1)	MR1 is defined as percentage of participants achieving a ratio of <=10% Breakpoint Cluster Region-abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.	3 months after the first dose of study treatment
Secondary	Percentage of Participants With Complete Hematologic Response (CHR)	CHR is defined as achieving all of the following measurements: white blood cells (WBC) <= institutional upper limit of normal (ULN), platelets <450,000 per cubic millimeter (/mm^3), no blasts or promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).	3 months after the first dose of study treatment
Secondary	Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption	An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.	Up to data cut-off: 31 May 2020 (Approximately 5 years)
Secondary	Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24	DOR (=1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for =1% BCR-ABL1IS are met until earliest date at which loss of =1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of =1% BCR-ABL1IS is an increase to >1% of BCR-ABL1IS. Progression to AP: =15% and <30% blasts in peripheral blood or bone marrow or =20% basophils in peripheral blood or bone marrow or =30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: =30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.	12 and 24 months after the first dose of study treatment
Secondary	Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)	Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to >0.1% of BCR-ABL1IS. Progression to AP: >= 15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts+promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.	12 and 24 months after the first dose of study treatment
Secondary	Duration of Response in Responders	Duration of response in "responders" is defined as any participants who achieved =1% BCR-ABL1IS at any time during the study. Responders are defined as those participants who meet all of the following: are randomized and treated, respond at 12 months after the initiation of study treatment, and undergo baseline polymerase chain reaction (PCR) assessment.	Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Secondary	Time to Response	Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to <10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.	Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Secondary	Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML	Progression to AP is defined as: >=15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.	From first dose date of study treatment up to data cut-off: 31 May 2020 (Approximately 5 years)
Secondary	Progression-free Survival (PFS)	PFS is defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression are met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP is defined as: >=15% and <30% blasts in peripheral blood or bone marrow or >=20% basophils in peripheral blood or bone marrow or >=30% blasts + promyelocytes in peripheral blood or bone marrow (but <30% blasts) or <100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: >=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.	Up to data cut-off: 31 May 2020 (Up to approximately 5 years)
Secondary	Overall Survival (OS)	OS is defined as the interval between the first does of study treatment and death due to any cause, censored at the last contact date when the participant was alive.	Up to data cut-off: 31 May 2020 (Up to approximately 5 years)

External Links

•   Iclusig® (ponatinib) US Prescribing Information